Atlanta, Georgia-based TendoNova is expanding the availability of its top product via a partnership with Tequesta, Florida-based AcCELLerated Biologics, LLC, a medical distribution company.
Partnership Expands Sales Network of Tendinopathy Treatment Device
1 min read Premium comments
Secondary#accellerationbiologics#ocelot#tendonova
The product is TendoNova’s Ocelot™ TSD 1000. The Ocelot received FDA 510(k) clearance a year ago. It is currently manufactured in Atlanta.
AcCELLerated Biologics CEO Steve Whyte said, “For the past decade, AcCELLerated Biologics has been at the forefront of training and equipping physicians with new biologic tools useful in the treatment of a variety of injuries.”
Whyte continued, “Working with TendoNova allows us to expand our offering to help improve the surgical treatment that could be combined with biologics to produce positive outcomes.”
According to TendoNova, the Ocelot Nano is “indicated for fragmentation and debridement of soft tissue.” The handheld device can be used in “percutaneous tenotomy to help disrupt scar tissue associated with tendinopathy.” The goal is to reinjure the tendon to stimulate the healing process.
The Ocelot can be used to treat a number of chronic tendon pain disorders. Per the press release, some of the tendinopathies that the Ocelot can treat include tennis elbow, plantar fasciitis, and jumper’s knee. It can be used in most settings including an ambulatory surgical center, hospital, or physician office.
TendoNova CEO Mark Samuels said, “The TendoNova Ocelot represents a great opportunity for improving the lives of over 30 million Americans affected by tendon pain.”
Finally, regarding the partnership itself, Samuels said, “Our partnership with AcCELLerated Biologics will enable access to customers for their biologic products that are utilized adjacent to our Ocelot.”
TendoNova may be improving the applications of the Ocelot in the near future. The company also indicated that it is developing a “digital health solution projected to provide device operating feedback during a procedure to reduce training times and improve outcomes.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.